CTOs on the Move

Accreditation Council for Graduate Medical Educa

www.acgme.org

 
The Accreditation Council for Graduate Medical Education (ACGME) is a private, non-profit, professional organization responsible for the accreditation of approximately 10,000 residency and fellowship programs and the approximately 800 institutions that sponsor these programs in the United States. Residency and fellowship programs educate approximately 125,000 resident and fellow physicians in 150 specialties and subspecialties. The ACGME`s mission is to improve health care and population health by assessing and advancing the quality of resident physicians` education through accreditation. We imagine a world characterized by: • A structured approach to evaluating the competency of all residents and fellows, • Motivated physician role ...
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.acgme.org
  • 401 North Michigan Avenue Suite 2000
    Chicago, IL USA 60611
  • Phone: 312.755.5000

Executives

Name Title Contact Details

Similar Companies

IntegraCare Home health

IntegraCare Home health is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Grapevine, TX. To find more information about IntegraCare Home health, please visit www.txhmg.com

Address

WRKOUT is the future of fitness - delivering premium personal training LIVE to any device. No recorded content. No expensive equipment.

Cummins Behavioral Health Systems

Cummins Behavioral Health Systems is a Avon, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kaiser Permanente Washington Health Research Institute

Kaiser Permanente Washington Health Research Institute (KPWHRI) is a non-profit research organization that conducts practical research to improve the health and health care of Kaiser Permanente members and the public.

Kymera Therapeutics

Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.